<abstract xml:lang="en" xmlns="http://www.w3.org/1999/xhtml"><bold>Background.</bold> The treatment of high-grade chondrosarcoma consists of either amputation or radical surgical resection of the tumour. Introducing protocols with neo-adjuvant chemotherapy improves survival rates in patients with a high-grade chondrosarcoma.<bold>Patients and methods.</bold> In 7 years period (2000-2006), 18 patients with chondrosarcoma were treated. Female were twice more than male (12/6). Patients age varied from 14 to 73 years (mean 51). Thirteen patients (72%) had extremities localised chondrosarcoma. Eight patients (8/13), or 62% with extremity localised high-grade chondrosarcoma were subjected to Scandinavian Sarcoma Group XVI chemotherapy protocol. Six of these patients (75%) complied with the criteria for limb salvage.<bold>Results.</bold> The follow up was from 13 months to 8 years (mean 32 months). Two patients (2/8) or 25% had primarily amputated limb. After the hystopathological assessment of the resected high-grade chondrosarcoma, 6/8 patients (75%) had bad response to neoadjuvant chemotherapy. There was local recurrence in 3/8 (37%) and metastases developed in 6/8 (75%) of the operated patients with high-grade chondrosarcoma. Two of 6 patients (33%) with limb-salvage had amputations due to local recurrence. Two patients (2/8), or 25%, survived more than 5 years, and up to date they are disease-free.<bold>Conclusions.</bold> Patients with extremities localised high-grade chondrosarcoma had higher survival rates and better functional outcome, compared to those with chondrosarcoma localised centrally.</abstract>

Background. The treatment of high-grade chondrosarcoma consists of either amputation or radical surgical resection of the tumour. Introducing protocols with neo-adjuvant chemotherapy improves survival rates in patients with a high-grade chondrosarcoma.Patients and methods. In 7 years period (2000-2006), 18 patients with chondrosarcoma were treated. Female were twice more than male (12/6). Patients age varied from 14 to 73 years (mean 51). Thirteen patients (72%) had extremities localised chondrosarcoma. Eight patients (8/13), or 62% with extremity localised high-grade chondrosarcoma were subjected to Scandinavian Sarcoma Group XVI chemotherapy protocol. Six of these patients (75%) complied with the criteria for limb salvage.Results. The follow up was from 13 months to 8 years (mean 32 months). Two patients (2/8) or 25% had primarily amputated limb. After the hystopathological assessment of the resected high-grade chondrosarcoma, 6/8 patients (75%) had bad response to neoadjuvant chemotherapy. There was local recurrence in 3/8 (37%) and metastases developed in 6/8 (75%) of the operated patients with high-grade chondrosarcoma. Two of 6 patients (33%) with limb-salvage had amputations due to local recurrence. Two patients (2/8), or 25%, survived more than 5 years, and up to date they are disease-free.Conclusions. Patients with extremities localised high-grade chondrosarcoma had higher survival rates and better functional outcome, compared to those with chondrosarcoma localised centrally.

Treatment of patients with "high grade" extremity localized chondrosarcoma. Preliminary results

Department for Musculoskeletal Tumours, Clinic for Orthopaedic Surgery, Skopje

Institute of Radiotherapy and Oncology, Skopje, Republic of Macedonia

Radiology and Oncology

Background. The treatment of high-grade chondrosarcoma consists of either amputation or radical surgical resection of the tumour. Introducing protocols with...

Treatment of patients with "high grade" extremity localized chondrosarcoma. Preliminary results

Publié en ligne: 14 sept. 2009

Pages: 187 - 194

DOI: https://doi.org/10.2478/v10019-009-0019-7

Mots clés
chondrosarcoma, limb-sparing, neo-adjuvant chemotherapy

This content is open access.

Treatment of patients with "high grade" extremity localized chondrosarcoma. Preliminary results

Publié en ligne: 14 sept. 2009

Pages: 187 - 194

DOI: https://doi.org/10.2478/v10019-009-0019-7

Mots cléschondrosarcoma, limb-sparing, neo-adjuvant chemotherapy

This content is open access.

Mots clés
chondrosarcoma, limb-sparing, neo-adjuvant chemotherapy